Bioventus (BVS) AI Stock Analysis

• Market Cap: $611.82M
• Dividend Yield: N/A
• Average Volume (3M): 520.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.95
• Revenue Growth: 5.08%
• EPS Growth: 99.38%
• Country: US
• Employees: 930
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Devices
• EPS (TTM): 0.21
• Shares Outstanding: 66,892,300
• 10 Day Avg. Volume: 512,286
• 30 Day Avg. Volume: 520,693
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.36
• Enterprise Value/Revenue: 1.47
• Enterprise Value/Gross Profit: 2.18
• Enterprise Value/Ebitda: 9.85
• 1Y Price Target: $12.88
• Price Target Upside: 82.95% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 56 Neutral
• Price Target: $7.50 ▲(6.53% Upside)

Bioventus's overall stock score is primarily influenced by its financial performance challenges, including declining revenue and high leverage. However, the company shows potential through improved cash flow and strategic growth opportunities highlighted in the earnings call and recent corporate events. The technical analysis suggests a neutral trend, while valuation remains a concern due to negative profitability metrics.

Positive Factors

Financial Performance

Cash flow from operations materially increased 71% to nearly $26M, indicating strong financial performance.

Growth Strategy

Bioventus has set in place levers to drive both short and long-term growth and expects a back-half improvement in its growth rate.

Valuation

Bioventus is trading at an attractive valuation, at half the multiple of its small-cap MedTech peers, supporting the analyst's recommendation to maintain a BUY rating.

Negative Factors

Earnings Pressure

Pain Treatments growth benefited from a few million dollars of above-normal distributor orders which BVS expects to negatively impact Q1 PT expectations as it sees lower Q1 distributor orders.

Revenue Expectations

Q1/H1 organic revenues should be more challenged given two fewer selling days in the Q1, pull-forward of HA orders from the Q1/25 to Q4/24, and continued BGS distributor choppiness for a couple more Qs.

Bioventus Business Overview & Revenue Model

Company Description

Bioventus Inc. (BVS) is a medical device company that specializes in developing and commercializing clinically effective and cost-efficient solutions for bone healing, bone graft, joint therapies, and biologics. The company primarily operates in the healthcare sector, focusing on orthopedic solutions that enhance patient outcomes and reduce healthcare costs. Bioventus offers a diverse portfolio of products, including minimally invasive therapies for osteoarthritis, bone graft substitutes, and devices that stimulate bone growth.

How the Company Makes Money

Bioventus generates revenue through the sale of its medical devices and biologic products to healthcare providers, including hospitals, clinics, and orthopedic specialists. The company's key revenue streams include product sales in the areas of bone healing, joint pain treatment, and bone graft solutions. Bioventus collaborates with healthcare professionals to ensure the effective integration of their products into treatment regimes, thereby driving sales. Additionally, Bioventus may engage in strategic partnerships and licensing agreements to expand its product offerings and market reach, which can also contribute to its earnings.

Bioventus Financial Statement Overview

Summary

Bioventus faces challenges with declining revenue and profitability, as reflected in its income statement. The balance sheet shows high leverage, which could pose financial risks if not managed properly. On the positive side, the company has improved its free cash flow, which is a critical factor for sustaining operations. Overall, while there are improvements in cash flow, the company needs to address its revenue decline and leverage to enhance financial stability.

Income Statement

Bioventus has shown a declining revenue trend with a negative revenue growth rate of -62.7% in the TTM period. The gross profit margin remains relatively stable at around 67%, but the net profit margin is negative, indicating ongoing profitability challenges. The EBIT and EBITDA margins have improved slightly in the TTM period but remain low, reflecting operational inefficiencies.

Balance Sheet

The company has a high debt-to-equity ratio of 2.34, indicating significant leverage. The return on equity is negative, suggesting that the company is not generating sufficient returns on its equity base. The equity ratio is not provided, but the high leverage poses potential financial risks.

Cash Flow

Bioventus has shown a positive free cash flow growth rate of 42.5% in the TTM period, indicating improved cash generation. However, the operating cash flow to net income ratio is low, suggesting that cash flow from operations is not strongly supporting net income. The free cash flow to net income ratio is relatively high, indicating that free cash flow is a significant component of net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	564.14M	573.28M	512.35M	512.12M	430.90M	321.16M
Gross Profit	381.35M	388.23M	328.19M	331.08M	302.71M	233.52M
EBITDA	84.42M	-49.55M	-23.07M	-121.61M	45.48M	52.06M
Net Income	-158.00K	-33.54M	-156.23M	-158.70M	19.38M	16.41M
Balance Sheet
Total Assets	706.79M	727.96M	810.91M	1.37B	1.23B	494.47M
Cash, Cash Equivalents and Short-Term Investments	32.91M	41.58M	36.96M	30.19M	43.93M	86.84M
Total Debt	341.24M	335.63M	394.85M	418.07M	357.68M	188.38M
Total Liabilities	505.49M	542.35M	589.79M	960.43M	692.07M	350.31M
Stockholders Equity	161.24M	147.94M	173.59M	325.24M	458.92M	144.16M
Cash Flow
Free Cash Flow	34.10M	37.79M	7.98M	-25.06M	15.62M	51.13M
Operating Cash Flow	36.24M	38.80M	15.34M	-13.54M	22.99M	71.80M
Investing Cash Flow	21.84M	22.96M	15.81M	-116.44M	-283.76M	-20.50M
Financing Cash Flow	-56.21M	-54.58M	-26.65M	62.08M	273.37M	-29.57M

Bioventus Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BVS, the sentiment is Negative. The current price of 7.04 is below the 20-day moving average (MA) of 7.26, above the 50-day MA of 6.90, and below the 200-day MA of 8.61, indicating a neutral trend. The MACD of 0.13 indicates Positive momentum. The RSI at 48.66 is Neutral, neither overbought nor oversold. The STOCH value of 26.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BVS.

Bioventus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AXGN	69 Neutral	$742.64M	―	-4.48%	―	17.17%	72.68%
SIBN	62 Neutral	$719.16M	―	-14.18%	―	22.93%	43.83%
BVS	56 Neutral	$611.82M	―	-0.10%	―	5.08%	99.38%
OFIX	54 Neutral	$591.62M	―	-24.63%	―	4.84%	0.85%
AVNS	54 Neutral	$554.05M	45.80	-46.17%	―	1.48%	-6091.13%
KIDS	54 Neutral	$521.53M	―	-11.49%	―	26.08%	-63.67%
Sector *	51 Neutral	$7.90B	-0.33	-41.69%	2.23%	23.45%	-1.99%

Bioventus Corporate Events

Bioventus Secures $400 Million Credit Agreement

On July 31, 2025, Bioventus LLC entered into a $400 million credit agreement with Wells Fargo Bank and other financial institutions. The agreement includes a $100 million revolving credit facility and a $300 million term loan, which will be used to refinance existing credit facilities. The credit facilities, secured by the company’s assets, will mature in 2030 and include various financial covenants and interest rates adjusted based on the company’s leverage ratio. This strategic financial move is expected to strengthen Bioventus’s financial position and operational flexibility.

Bioventus Gains FDA Clearance for Key PNS Products

On July 30, 2025, Bioventus Inc. announced that it received FDA 510(k) clearances for its TalisMann™ and StimTrial™ products, expanding its Peripheral Nerve Stimulation portfolio aimed at chronic pain management. This milestone presents a significant growth opportunity for Bioventus as it seeks to capitalize on the rapidly growing PNS market, which is projected to exceed $500 million by 2029. The FDA clearance allows Bioventus to offer a comprehensive PNS portfolio, enhancing its market positioning by providing non-opioid, minimally invasive therapies that address clinical needs, and facilitating broader physician adoption and payer reimbursement.

Bioventus Holds Annual Meeting, Elects Directors

On June 3, 2025, Bioventus, Inc. held its Annual Meeting of Stockholders, where approximately 89.76% of the outstanding shares were represented. During the meeting, stockholders elected Class I directors to the Board and ratified Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.